We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

Aggrenox End-Payors Want $18M Atty Fees In $54M Deal

Law360 (April 13, 2018, 8:20 PM EDT) -- Indirect buyers of Aggrenox told a Connecticut federal judge Friday that attorneys who represented the putative class alleging that Teva Pharmaceutical and Boehringer Ingelheim blocked generic alternatives to the stroke-prevention drug...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.